Healthcare Sales & Marketing Network News: Vedolizumab

Searching News Database: Vedolizumab

HSMN NewsFeed - 17 Feb 2022
Prometheus Laboratories Announces the Launch of PredictrPK(TM) IFX, A Revolutionary Test Enabling Precision-Guided Dosing for Inflammatory Bowel Disease
Diagnostics Gastroenterology Product Launch

HSMN NewsFeed - 5 Jul 2016
Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease
Biopharmaceuticals Regenerative Medicine Licensing

HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 11 May 2012
Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases
Biopharmaceuticals Gastroenterology

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.